◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Astellas Pharma Inc. (4503)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-10-02
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma.
关键数据
- 市值: JPY 4.03 trillion
- 收入（截至 2026-03-31 财年）: JPY 2.14T
- 净利润: JPY 291.5B
- 毛利率: 80.9%
- 净利率: 13.6%
查看交互式图表与完整报表 →
估值模型 (DCF) →
年度利润表
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|
| 总收入 | JPY 2.14T | JPY 1.91T | JPY 1.60T | JPY 1.52T |
| 毛利 | JPY 1.73T | JPY 1.56T | JPY 1.31T | JPY 1.23T |
| 营业利润（EBIT） | JPY 380.1B | JPY 40.2B | JPY 18.9B | JPY 131.6B |
| 净利 | JPY 291.5B | JPY 50.7B | JPY 17.0B | JPY 98.7B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 4503 交互式查看器。 /companies/us/4503
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.